Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Reporting results of cancer treatment

1981 • 7,916 citations

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

1997 • 5,683 citations

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1996 • 3,395 citations

Improving the Quality of Reporting of Randomized Controlled Trials

1996 • 2,811 citations

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

1995 • 2,804 citations

Prognostic effect of weight loss prior tochemotherapy in cancer patients

1980 • 2,298 citations

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1975 • 2,224 citations

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

1988 • 704 citations

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1993 • 498 citations

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1994 • 444 citations

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1993 • 394 citations

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

1994 • 376 citations

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

1994 • 364 citations

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

2000 • 333 citations

Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer

1994 • 307 citations

Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)

1993 • 293 citations

Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

1996 • 246 citations

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1997 • 193 citations

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

1990 • 155 citations

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.

1997 • 149 citations

Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

1997 • 116 citations

Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia

1990 • 79 citations

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.

1990 • 78 citations

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.

1991 • 69 citations

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1991 • 42 citations

950 Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe

1995 • 30 citations

Hemolytic-uremic syndrome caused by gemcitabine

1998 • 21 citations

Measurable or assessable disease in lung cancer trials: does it matter?

1994 • 16 citations

Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer?

1998 • 10 citations